AGA Recommends Endoscopic Removal of Precancerous Cells in Patients With High-Risk Barrett’s Esophagus

Endoscopic removal of precancerous cells in patients with confirmed, high-risk Barrett’s esophagus is recommended over surveillance, according to a medical position statement by the American Gastroenterological Institute.

Advertisement

The AGA recommends endoscopic eradication therapy with radiofrequency ablation, photodynamic therapy or endoscopic mucosal resection, as follows for various patient groups:

•    Patients with confirmed high-grade dysplasia (advanced precancerous cells): endoscopic eradication therapy is recommended.
•    Patients with confirmed low-grade dysplasia (beginning precancerous cells): endoscopic eradication therapy is a treatment option and should be discussed with patients as such.
•    Patients with Barrett’s esophagus without abnormal cells: endoscopic eradication therapy is not recommended.

If eradication therapy is not indicated, is not available or is declined by a patient with Barrett’s esophagus, surveillance by endoscopy should be performed every three months in patients with high-grade dysplasia; every six to 12 months in patients with low-grade dysplasia; and every three to five years in patients with no dysplasia.

Read the AGA news release about endoscopic removal of pre-cancerous cells in patients with high-risk Barrett’s esophagus.

Read other coverage about Barrett’s esophagus:

– Light and Sensors Can Help Detect Esophageal Cancer

– RFA and Endoscopy Treatment May Prevent Barrett’s Esophagus Patients From Surgery

– GI Studies Focus on Barrett’s Esophagus, Endoscopic Ultrasound

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.